Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HRS-4029 in Healthy Subjects
NCT06905314Phase 1Not yet recruiting
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of HRS-4029 in ischemic stroke (6 arms), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoint: Incidence and severity of adverse events at Day 15. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
HRS-4029
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06905314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905314.